TrialDiabetologia2015

Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial.

Sabita S Soedamah-Muthu et al.PubMed ↗Full text ↗Publisher ↗

A secondary analysis of NCT00327418. The report of the trial’s main result is not on the map, and the numbers here are shown and do not vote.

What the trial testedrandomised · 2,322 people · 2015

Randomised comparison

Lowered inflammation & biomarkers

Doesn’t vote: a later paper about the trial

−32.0percentage points−40.0 to −22.0

As reported

difference −32.0 %, 95% CI −40.0 to −22.0

Range includes no effect

No clear effect on inflammation & biomarkers

Doesn’t vote: a later paper about the trial

+17%−6% to +45%

Bigger than 3 in 10 on the map

As reported

HR 1.17, 95% CI 0.94–1.45

+1 more in the walkthrough ↓

Three numbers in the abstract

the abstract, start to end

… arm showed a net CRP lowering of 32% (95% CI -40%, -22%) compared …

… reduced LDL-cholesterol levels by 42% (p < 0.0001) from baseline to …

… a weak, non-significant association (HR 1.17 [95% CI 0.94, 1.45]) between …

← favours treatmentfavours comparator →

could be chance

No interval given · direction only, strength unknown

Inflammation & biomarkers

−32.0−40.0 to −22.0

Lipids

−42.0

Inflammation & biomarkers

HR 1.170.94–1.45

StatinsLipidsInflammation & biomarkers

1 / 3

19 papers cite it

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

this paperpooled ittrialcites it

The trial

NCT00327418phase 42,800 enrolled1997a later paper about it